PE20120899A1 - Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b - Google Patents

Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b

Info

Publication number
PE20120899A1
PE20120899A1 PE2011001908A PE2011001908A PE20120899A1 PE 20120899 A1 PE20120899 A1 PE 20120899A1 PE 2011001908 A PE2011001908 A PE 2011001908A PE 2011001908 A PE2011001908 A PE 2011001908A PE 20120899 A1 PE20120899 A1 PE 20120899A1
Authority
PE
Peru
Prior art keywords
seq
nos
complement protein
compositions
methods
Prior art date
Application number
PE2011001908A
Other languages
English (en)
Inventor
Bijan Etemad-Gilbertson
Braydon Charles Guild
Yong-In Kim
Ingo Klagge
Alexandra Kraus
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120899A1 publication Critical patent/PE20120899A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL HUMANIZADO DE UNA SOLA CADENA QUE SE ENLAZA A UNA PROTEINA DE COMPLEMENTO C3b CON UNA KD MENOR O IGUAL A 250PM QUE COMPRENDE: (I)UNA CADENA PESADA COMPRENDE: (A) UNA CDR1 CON SELECCIONADA DE SEQ ID NºS: 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169,183 Y 7, 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, 175 Y 189; (B) UNA CDR2 SELECCIONADAS DE SEQ ID NºS: 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170 Y 184; (C) UNA CDR3 SELECCIONADAS DE SEQ NºS: 3, 17, 31, 45, 59, 73, 87, 101, 115, 129, 143, 157, 171 Y 185; Y (II) UNA CADENA LIGERA COMPRENDE: (A) UNA CDR1 SELECCIONADAS DE SEQ ID NºS: 4, 18, 32, 46, 60, 74, 88, 102, 116, 130, 144, 158, 172, 186 Y 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176 Y 190; (B) UNA CDR2 SELECCIONADAS DE SEQ NºS: 5, 19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173 Y 187; (C) UNA CDR3 SELECCIONADAS DE SEQ ID NºS: 6, 20, 34, 48, 62, 76, 90, 104, 118, 132, 146, 160, 174 Y 188. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO QUE INHIBE LA SENDA DEL COMPLEMENTO ALTERNATIVA Y ES UTIL EN EL TRATAMIENTO DE DEGENERACION MACULAR
PE2011001908A 2009-05-06 2010-05-05 Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b PE20120899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06

Publications (1)

Publication Number Publication Date
PE20120899A1 true PE20120899A1 (es) 2012-08-03

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001908A PE20120899A1 (es) 2009-05-06 2010-05-05 Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b

Country Status (22)

Country Link
US (1) US20100291106A1 (es)
EP (1) EP2427491A2 (es)
JP (1) JP2012525829A (es)
KR (1) KR20120088551A (es)
CN (1) CN102459334A (es)
AR (1) AR076655A1 (es)
AU (1) AU2010252156A1 (es)
CA (1) CA2760757A1 (es)
CL (1) CL2011002756A1 (es)
CO (1) CO6440515A2 (es)
EA (1) EA201101593A1 (es)
EC (1) ECSP11011445A (es)
IL (1) IL216061A0 (es)
MA (1) MA33402B1 (es)
MX (1) MX2011011754A (es)
PE (1) PE20120899A1 (es)
SG (1) SG175432A1 (es)
TN (1) TN2011000528A1 (es)
TW (1) TW201043638A (es)
UY (1) UY32612A (es)
WO (1) WO2010136311A2 (es)
ZA (1) ZA201107551B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
KR20120130748A (ko) 2009-11-05 2012-12-03 알렉시온 캠브리지 코포레이션 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
CN103261893A (zh) * 2010-11-29 2013-08-21 诺沃姆德治疗公司 用于诊断组织损害的新抗体
WO2013152024A1 (en) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor c3 antibodies and uses thereof
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP3722320A3 (en) * 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
US9657111B2 (en) * 2012-11-29 2017-05-23 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein C and uses thereof
ES2768648T3 (es) 2013-03-29 2020-06-23 Alexion Pharma Inc Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins
AU2014332021B2 (en) * 2013-10-07 2020-05-07 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
JP6643244B2 (ja) 2014-02-27 2020-02-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
MX2020010323A (es) * 2018-04-03 2021-01-08 Ngm Biopharmaceuticals Inc Agentes de union al componente del complemento c3 (c3) y metodos para su uso.
EP4257602A3 (en) * 2018-06-11 2023-12-27 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CA3214281A1 (en) * 2021-03-19 2022-09-22 Elpis Biopharmaceuticals Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2316446T3 (es) * 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
US20090004183A1 (en) * 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
BRPI0518622A2 (pt) * 2004-12-02 2008-12-02 Domantis Ltd usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
KR101472250B1 (ko) * 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
KR101572700B1 (ko) * 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares

Also Published As

Publication number Publication date
WO2010136311A3 (en) 2011-05-26
CL2011002756A1 (es) 2012-03-23
CN102459334A (zh) 2012-05-16
SG175432A1 (en) 2011-12-29
MA33402B1 (fr) 2012-07-03
TW201043638A (en) 2010-12-16
UY32612A (es) 2010-12-31
ZA201107551B (en) 2012-07-25
CA2760757A1 (en) 2010-12-02
IL216061A0 (en) 2012-01-31
KR20120088551A (ko) 2012-08-08
JP2012525829A (ja) 2012-10-25
EP2427491A2 (en) 2012-03-14
WO2010136311A2 (en) 2010-12-02
EA201101593A1 (ru) 2012-06-29
MX2011011754A (es) 2011-11-29
US20100291106A1 (en) 2010-11-18
CO6440515A2 (es) 2012-05-15
ECSP11011445A (es) 2012-01-31
AU2010252156A1 (en) 2011-11-10
AR076655A1 (es) 2011-06-29
TN2011000528A1 (en) 2013-05-24

Similar Documents

Publication Publication Date Title
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
PE20131209A1 (es) Anticuerpos anti-fap
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20081186A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
PE20140247A1 (es) Anticuerpos anti-cd38
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20141017A1 (es) Anticuerpos del cea
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
PE20200695A1 (es) Anticuerpos que reconocen tau
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
PE20120014A1 (es) Anticuerpos humanos de alta afinidad contra pcsk9

Legal Events

Date Code Title Description
FA Abandonment or withdrawal